FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912147283> ?p ?o ?g. }

• W2912147283 endingPage "238146831881884" @default.
• W2912147283 startingPage "238146831881884" @default.
• W2912147283 abstract "Introduction. Given the lack of independent analyses comparing numerous pharmacotherapies for osteoporosis, the study objective was to identify the optimal osteoporosis treatment based on a woman’s age, fracture history, and ability to tolerate oral bisphosphonates adopting practices recommended in the recently revised Canadian guidelines. Methods. A cost utility analysis from the health care system perspective compared alendronate, etidronate, risedronate, zoledronate, denosumab, and no pharmacotherapy using a Markov model incorporating data on fracture risk and their associated costs, mortality, and disutility and treatment effect. Stratified analysis was conducted based on age, fracture history, and ability to tolerate oral bisphosphonates. Expected lifetime outcomes were obtained through probabilistic analysis with scenario analyses addressing methodological and structural uncertainty. Results. For women able to tolerate oral bisphosphonates, risedronate and etidronate were dominated. Compared to no therapy, alendronate was either dominant or was associated with a low incremental cost per QALY (quality-adjusted life years) gained (ICER)—less than CAN$3,751 based on age and fracture history. In comparison with alendronate, both zoledronate and denosumab were either dominated or associated with a high ICER—greater than CAN$660,000 per QALY. For women unable to tolerate bisphosphonates, dependent on age and fracture history, the ICER for zoledronate versus no therapy ranged from CAN$17,770 to CAN$94,365 per QALY. For all strata, denosumab was dominated by zoledronate or had an ICER greater than CAN$3.0 million. Scenario analyses found consistent findings. Conclusions. Based on a threshold of CAN$50,000 per QALY, alendronate is optimal for osteoporotic women who can tolerate oral bisphosphonates regardless of age or fracture history. For women unable to tolerate oral bisphosphonates, zoledronate is optimal for women with previous fracture or aged 80 to 84 or over 90 with no previous fracture." @default.
• W2912147283 created "2019-02-21" @default.
• W2912147283 creator A5028874004 @default.
• W2912147283 date "2019-01-01" @default.
• W2912147283 modified "2023-09-26" @default.
• W2912147283 title "Cost-Effectiveness of Pharmacological Treatments for Osteoporosis Consistent with the Revised Economic Evaluation Guidelines for Canada" @default.
• W2912147283 cites W1496200971 @default.
• W2912147283 cites W1556686277 @default.
• W2912147283 cites W1966813919 @default.
• W2912147283 cites W1971116094 @default.
• W2912147283 cites W1978445192 @default.
• W2912147283 cites W1986659095 @default.
• W2912147283 cites W1986986986 @default.
• W2912147283 cites W1989950790 @default.
• W2912147283 cites W1994955754 @default.
• W2912147283 cites W2014026657 @default.
• W2912147283 cites W2021748249 @default.
• W2912147283 cites W2024158966 @default.
• W2912147283 cites W2026500950 @default.
• W2912147283 cites W2029403036 @default.
• W2912147283 cites W2033596818 @default.
• W2912147283 cites W2036125852 @default.
• W2912147283 cites W2037040844 @default.
• W2912147283 cites W2038361874 @default.
• W2912147283 cites W2046036648 @default.
• W2912147283 cites W2061450074 @default.
• W2912147283 cites W2067734513 @default.
• W2912147283 cites W2079217360 @default.
• W2912147283 cites W2083754422 @default.
• W2912147283 cites W2094967524 @default.
• W2912147283 cites W2096966227 @default.
• W2912147283 cites W2097672482 @default.
• W2912147283 cites W2114529215 @default.
• W2912147283 cites W2130188153 @default.
• W2912147283 cites W2130922075 @default.
• W2912147283 cites W2137073779 @default.
• W2912147283 cites W2149072264 @default.
• W2912147283 cites W2158694566 @default.
• W2912147283 cites W2160005424 @default.
• W2912147283 cites W2162647625 @default.
• W2912147283 cites W2172119280 @default.
• W2912147283 cites W2189576889 @default.
• W2912147283 cites W2419672284 @default.
• W2912147283 cites W2530889824 @default.
• W2912147283 cites W2570418334 @default.
• W2912147283 cites W2614075773 @default.
• W2912147283 doi "https://doi.org/10.1177/2381468318818843" @default.
• W2912147283 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6357295" @default.
• W2912147283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30729168" @default.
• W2912147283 hasPublicationYear "2019" @default.
• W2912147283 type Work @default.
• W2912147283 sameAs 2912147283 @default.
• W2912147283 citedByCount "10" @default.
• W2912147283 countsByYear W29121472832020 @default.
• W2912147283 countsByYear W29121472832021 @default.
• W2912147283 countsByYear W29121472832022 @default.
• W2912147283 crossrefType "journal-article" @default.
• W2912147283 hasAuthorship W2912147283A5028874004 @default.
• W2912147283 hasBestOaLocation W29121472831 @default.
• W2912147283 hasConcept C112930515 @default.
• W2912147283 hasConcept C126322002 @default.
• W2912147283 hasConcept C1862650 @default.
• W2912147283 hasConcept C187212893 @default.
• W2912147283 hasConcept C2776286101 @default.
• W2912147283 hasConcept C2776541429 @default.
• W2912147283 hasConcept C3019080777 @default.
• W2912147283 hasConcept C515549039 @default.
• W2912147283 hasConcept C64332521 @default.
• W2912147283 hasConcept C71924100 @default.
• W2912147283 hasConceptScore W2912147283C112930515 @default.
• W2912147283 hasConceptScore W2912147283C126322002 @default.
• W2912147283 hasConceptScore W2912147283C1862650 @default.
• W2912147283 hasConceptScore W2912147283C187212893 @default.
• W2912147283 hasConceptScore W2912147283C2776286101 @default.
• W2912147283 hasConceptScore W2912147283C2776541429 @default.
• W2912147283 hasConceptScore W2912147283C3019080777 @default.
• W2912147283 hasConceptScore W2912147283C515549039 @default.
• W2912147283 hasConceptScore W2912147283C64332521 @default.
• W2912147283 hasConceptScore W2912147283C71924100 @default.
• W2912147283 hasIssue "1" @default.
• W2912147283 hasLocation W29121472831 @default.
• W2912147283 hasLocation W29121472832 @default.
• W2912147283 hasLocation W29121472833 @default.
• W2912147283 hasLocation W29121472834 @default.
• W2912147283 hasLocation W29121472835 @default.
• W2912147283 hasOpenAccess W2912147283 @default.
• W2912147283 hasPrimaryLocation W29121472831 @default.
• W2912147283 hasRelatedWork W2108723005 @default.
• W2912147283 hasRelatedWork W2111261443 @default.
• W2912147283 hasRelatedWork W2888781914 @default.
• W2912147283 hasRelatedWork W2912147283 @default.
• W2912147283 hasRelatedWork W2999748892 @default.
• W2912147283 hasRelatedWork W3119655573 @default.
• W2912147283 hasRelatedWork W3199327916 @default.
• W2912147283 hasRelatedWork W4224326059 @default.
• W2912147283 hasRelatedWork W87759024 @default.
• W2912147283 hasRelatedWork W2531417675 @default.
• W2912147283 hasVolume "4" @default.

• next